How rituximab affects immune cells in adults with membranous nephropathy
Studies blood immune cells in 12 adults with membranous nephropathy given rituximab.
Key facts
- Who runs it
- Centre Hospitalier Universitaire de Nice
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Single-cell RNA Sequencing (scRNA-seq) to Investigate the Mechanisms Underlying the Induction of Regulatory T Cells in Patients With Extramembranous Glomerulonephritis Treated With Rituximab
- Status
- Not yet recruiting
- People taking part
- 12 people, planned
- Started
- 31 Oct 2026
- Expected to end
- 31 Oct 2029
- Type of study
- Interventional
- Treatments tested
- Peripheral blood immune-cell profiling by single-cell RNA sequencing and in vitro pathway modulation assays
- Record updated
- 10 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with active anti-PLA2R1-positive membranous nephropathy, a kidney disease, who are due to get rituximab as part of usual care. Extra blood samples are taken to study immune cells.
- Age
- 18 Years and older
- Sex
- All
- Disease stage
- Active nephrotic syndrome: urine protein/creatinine ratio >3.5 g/g and blood albumin <30 g/L. Kidney filtration (eGFR, CKD-EPI) >30 mL/min/1.73 m2.
- Earlier treatment
- Must have a reason to get rituximab in routine care. No treatment that weakens the immune system in the previous 6 months.
- Biomarker or test result
- Anti-PLA2R1 antibody positive.
Main reasons for not taking part
- Treatment that weakens the immune system within the previous 6 months
- Pregnant or breastfeeding, or no effective birth control when needed
- Minors, adults under guardianship or curatorship, people deprived of liberty
- Not covered by French social security or not fluent in French
- Stopping before getting both rituximab infusions
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Signed informed consent
- Anti-PLA2R1-positive membranous nephropathy
- Active nephrotic syndrome, defined as urinary protein/creatinine ratio >3.5 g/g and serum albumin <30 g/L
- Indication for rituximab treatment as part of routine care
- Estimated glomerular filtration rate calculated using the CKD-EPI equation >30 mL/min/1.73 m2
Who cannot take part
- Immunosuppressive treatment received within the previous 6 months
- Lack of affiliation to the French social security system
- Vulnerable person, including minors, adults under guardianship or curatorship, pregnant women, persons deprived of liberty, or persons who do not master the French language
- Breastfeeding
- Absence of effective contraception, when applicable
- Premature discontinuation before administration of both rituximab infusions
- Voluntary withdrawal of informed consent or objection to the use of study data or biological samples
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Membranous nephropathy is a rare autoimmune kidney disease in which autoantibodies, most commonly anti-PLA2R1 antibodies, target podocyte antigens and may cause nephrotic syndrome. Rituximab is used in routine care to deplete B cells and reduce pathogenic autoantibodies, but its effects are not limited to B-cell depletion. Previous work suggests that rituximab may also promote regulatory T-cell (Treg) responses, and higher Treg levels after treatment have been associated with clinical remission.
Read full original descriptionShow less
TRANSCRIPT is a prospective, single-center, pilot mechanistic study in 12 adult patients with active anti-PLA2R1-positive membranous nephropathy who have an indication for rituximab as part of routine care. Participants will receive rituximab according to usual clinical practice (1 g on Day 0 and 1 g on Day 15). Additional blood samples will be collected at Day 0 and Month 6 to isolate peripheral immune cells. Single-cell RNA sequencing will be used to identify transcriptional changes, signaling pathways, and intercellular communication networks associated with rituximab-induced Treg induction. In vitro assays will then test modulators of the candidate pathways identified by sequencing.
The study hypothesis is that rituximab modulates immune-cell signaling and communication pathways that contribute to the induction of regulatory T cells in patients with membranous nephropathy.
The group in the trial
- Rituximab-treated anti-PLA2R1-positive membranous nephropathy patientsOther group
Treatment: Peripheral blood immune-cell profiling by single-cell RNA sequencing and in vitro pathway modulation assays
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Study Using Single-cell RNA Sequencing (scRNA-seq) to Investigate the Mechanisms Underlying the Induction of Regulatory T Cells in Patients With Extramembranous Glomerulonephritis Treated With Rituximab
- Plain-language title
- How rituximab affects immune cells in adults with membranous nephropathyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 10 September 2026